Taiqian Gong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Taiqian Gong has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
Shouyin Di
Department of Thoracic Surgery, The Sixth Medical Center of Chinese, PLA General Hospital, Beijing, China
6 shared publicationsShun Xie
Navy Clinical College, the Fifth School of Clinical Medicine, Anhui Medical University, Hefei, China
5 shared publications- Boshi Fan
Department of Thoracic Surgery, The Sixth Medical Center of PLA General Hospital of Beijing, Beijing, China
4 shared publications Guanghui Xu
State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi’an, People’s Republic of China
4 shared publicationsGuohong Zhao
State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi’an, People’s Republic of China
4 shared publicationsJiale Zhang
Department of Thoracic Surgery, The Sixth Medical Center of Chinese, PLA General Hospital, Beijing, China
4 shared publications
Latest Publications
- Open Access
- 2 May 2026
- Published by Springer Nature in Discover Nano
- Vol. 21 (1) , 157
Engineering L-Arg@ZIF-8 nanoparticles to modulate the immune–osteogenic–angiogenic microenvironment for accelerated bone fracture healing
Bone fracture healing requires coordinated regulation of osteogenesis, angiogenesis, and immune homeostasis within a dynamically evolving microenvironment.
- 2 May 2026
- Published by Springer Nature in Discover Nano
- Vol. 21 (1) , 157
Open AccessEngineering L-Arg@ZIF-8 nanoparticles to modulate the immune–osteogenic–angiogenic microenvironment for accelerated bone fracture healing
Bone fracture healing requires coordinated regulation of osteogenesis, angiogenesis, and immune homeostasis within a dynamically evolving microenvironment.
- Open Access
- 31 October 2025
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 20 (1) , 1-5
A mediastinal eosinophilic adenoma misdiagnosed as an esophageal stromal tumor: A case report
Eosinophilic adenoma, a benign tumor characterized by eosinophilic cell proliferation, typically arises in endocrine organs such as the thyroid or parathyroid glands. Ectopic parathyroid eosinophilic adenoma is rare and may mimic other mediastinal pathologies, leading to diagnostic challenges. We present a case of a 54-year-old woman with a one-year history of dysphagia. Initial imaging and endoscopic studies suggested an esophageal stromal tumor. Thoracoscopic resection revealed a posterior mediastinal mass, later confirmed as an ectopic parathyroid eosinophilic adenoma through histopathological and immunohistochemical analysis. This case underscores the importance of integrating imaging, laboratory tests, and histopathology for accurate diagnosis of mediastinal masses. Minimally invasive thoracoscopic surgery proved effective for resection, highlighting the need for tailored therapeutic approaches. In order to avoid such misdiagnosis, clinicians should make a definite pathological diagnosis before surgery as much as possible.
- 31 October 2025
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 20 (1) , 1-5
Open AccessA mediastinal eosinophilic adenoma misdiagnosed as an esophageal stromal tumor: A case report
Eosinophilic adenoma, a benign tumor characterized by eosinophilic cell proliferation, typically arises in endocrine organs such as the thyroid or parathyroid glands. Ectopic parathyroid eosinophilic adenoma is rare and may mimic other mediastinal pathologies, leading to diagnostic challenges. We present a case of a 54-year-old woman with a one-year history of dysphagia. Initial imaging and endoscopic studies suggested an esophageal stromal tumor. Thoracoscopic resection revealed a posterior mediastinal mass, later confirmed as an ectopic parathyroid eosinophilic adenoma through histopathological and immunohistochemical analysis. This case underscores the importance of integrating imaging, laboratory tests, and histopathology for accurate diagnosis of mediastinal masses. Minimally invasive thoracoscopic surgery proved effective for resection, highlighting the need for tailored therapeutic approaches. In order to avoid such misdiagnosis, clinicians should make a definite pathological diagnosis before surgery as much as possible.
- Open Access
- 1 July 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (7) , 3437-3445
Short-term outcomes of three- and two-field lymphadenectomy with minimally invasive esophagectomy for esophageal cancer: a propensity score-matching analysis
Background: Whether patients can benefit from three-field lymphadenectomy (3-FL) in minimally invasive esophagectomy (MIE) remains unclear. This study retrospectively compared short-term outcomes between 3-FL and two-field lymphadenectomy (2-FL) in MIE for patients with esophageal cancer (EC) and aimed to evaluate the clinical significance of 3-FL. Methods: There were 284 patients enrolled in the study (124 patients with 3-FL and 160 patients with 2-FL). The cases were matched based on their propensity scores using a matching ratio of 1:1, the nearest neighbor matching protocol, and a caliper of 0.02. Patients were propensity-score matched for sex, cancer location, Age-adjusted Charlson Comorbidity Index (ACCI), and neoadjuvant treatment. The short-term outcomes were postoperative complications, operation characteristics, pathology results and postoperative hospital stay. Results: There were no significant differences in intraoperative hemorrhage, postoperative hospital stay, or postoperative complications between the 2-FL and 3-FL groups. The operation time of the two groups was significantly different (227.1±46.2 vs. 248.5±45.9 min, P=0.001); the operation time of the 3-FL group was about 20 minutes longer than that of the 2-FL group. The number of lymphatic nodes (LNs) obtained in the 3-FL group was significantly higher than that in the 2-FL group (31.3±12.9 vs. 54.6±18.0, PConclusions: Compared to 2-FL MIE, 3-FL MIE does not increase postoperative complications, can obtain more LNs, and improves the accuracy of tumor LN staging.
- 1 July 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (7) , 3437-3445
Open AccessShort-term outcomes of three- and two-field lymphadenectomy with minimally invasive esophagectomy for esophageal cancer: a propensity score-matching analysis
Background: Whether patients can benefit from three-field lymphadenectomy (3-FL) in minimally invasive esophagectomy (MIE) remains unclear. This study retrospectively compared short-term outcomes between 3-FL and two-field lymphadenectomy (2-FL) in MIE for patients with esophageal cancer (EC) and aimed to evaluate the clinical significance of 3-FL. Methods: There were 284 patients enrolled in the study (124 patients with 3-FL and 160 patients with 2-FL). The cases were matched based on their propensity scores using a matching ratio of 1:1, the nearest neighbor matching protocol, and a caliper of 0.02. Patients were propensity-score matched for sex, cancer location, Age-adjusted Charlson Comorbidity Index (ACCI), and neoadjuvant treatment. The short-term outcomes were postoperative complications, operation characteristics, pathology results and postoperative hospital stay. Results: There were no significant differences in intraoperative hemorrhage, postoperative hospital stay, or postoperative complications between the 2-FL and 3-FL groups. The operation time of the two groups was significantly different (227.1±46.2 vs. 248.5±45.9 min, P=0.001); the operation time of the 3-FL group was about 20 minutes longer than that of the 2-FL group. The number of lymphatic nodes (LNs) obtained in the 3-FL group was significantly higher than that in the 2-FL group (31.3±12.9 vs. 54.6±18.0, PConclusions: Compared to 2-FL MIE, 3-FL MIE does not increase postoperative complications, can obtain more LNs, and improves the accuracy of tumor LN staging.
- 9 January 2024
- Published by Springer Nature in Neurotoxicity Research
- Vol. 42 (1) , 1-11
Monoclonal Antibody Targeting CGRP Relieves Cisplatin-Induced Neuropathic Pain by Attenuating Neuroinflammation
Chemotherapy-induced neuropathic pain (CIPN) is a common side effect of antitumor chemotherapeutic agents. It describes a pathological state of pain related to the cumulative dosage of the drug, significantly limiting the efficacy of antitumor treatment. Sofas strategies alleviating CIPN still lack. Calcitonin gene-related peptide (CGRP) is a neuropeptide involved in many pathologic pains. In this study, we explored the effects of CGRP blocking on CIPN and potential mechanisms. Total dose of 20.7 mg/kg cisplatin was used to establish a CIPN mouse model. Mechanical and thermal hypersensitivity was measured using von Frey hairs and tail flick test. Western blot and immunofluorescence were utilized to evaluate the levels of CGRP and activated astrocytes in mouse spinal cord, respectively. In addition, real-time quantitative PCR (RT-qPCR) was used to detect the level of inflammatory cytokines such as IL-6, IL-1β, and NLRP3 in vitro and in vivo. There are markedly increased CGRP expression and astrocyte activation in the spinal cord of mice following cisplatin treatment. Pretreatment with a monoclonal antibody targeting CGRP (ZR8 mAb) effectively reduced cisplatin-induced mechanical hypersensitivity and thermal nociceptive sensitization and attenuated neuroinflammation as marked by downregulated expression of IL-6, IL-1β, and NLRP3 in the mice spinal cord and spleen. Lastly, ZR8 mAb does not interfere with the antitumor effects of cisplatin in tumor-bearing mice. Our findings indicate that neutralizing CGRP with monoclonal antibody could effectively alleviate CIPN by attenuating neuroinflammation. CGRP is a promising therapeutic target for CIPN.
- 9 January 2024
- Published by Springer Nature in Neurotoxicity Research
- Vol. 42 (1) , 1-11
Monoclonal Antibody Targeting CGRP Relieves Cisplatin-Induced Neuropathic Pain by Attenuating Neuroinflammation
Chemotherapy-induced neuropathic pain (CIPN) is a common side effect of antitumor chemotherapeutic agents. It describes a pathological state of pain related to the cumulative dosage of the drug, significantly limiting the efficacy of antitumor treatment. Sofas strategies alleviating CIPN still lack. Calcitonin gene-related peptide (CGRP) is a neuropeptide involved in many pathologic pains. In this study, we explored the effects of CGRP blocking on CIPN and potential mechanisms. Total dose of 20.7 mg/kg cisplatin was used to establish a CIPN mouse model. Mechanical and thermal hypersensitivity was measured using von Frey hairs and tail flick test. Western blot and immunofluorescence were utilized to evaluate the levels of CGRP and activated astrocytes in mouse spinal cord, respectively. In addition, real-time quantitative PCR (RT-qPCR) was used to detect the level of inflammatory cytokines such as IL-6, IL-1β, and NLRP3 in vitro and in vivo. There are markedly increased CGRP expression and astrocyte activation in the spinal cord of mice following cisplatin treatment. Pretreatment with a monoclonal antibody targeting CGRP (ZR8 mAb) effectively reduced cisplatin-induced mechanical hypersensitivity and thermal nociceptive sensitization and attenuated neuroinflammation as marked by downregulated expression of IL-6, IL-1β, and NLRP3 in the mice spinal cord and spleen. Lastly, ZR8 mAb does not interfere with the antitumor effects of cisplatin in tumor-bearing mice. Our findings indicate that neutralizing CGRP with monoclonal antibody could effectively alleviate CIPN by attenuating neuroinflammation. CGRP is a promising therapeutic target for CIPN.
- 21 November 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 253, 154964
TESC acts as a prognostic factor and promotes epithelial-mesenchymal transition progression in esophageal squamous carcinoma
- 21 November 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 253, 154964
TESC acts as a prognostic factor and promotes epithelial-mesenchymal transition progression in esophageal squamous carcinoma
- 11 November 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 252, 154945
FAM107A as a tumor suppressor in esophageal squamous carcinoma inhibits growth and metastasis
- 11 November 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 252, 154945
FAM107A as a tumor suppressor in esophageal squamous carcinoma inhibits growth and metastasis
- Open Access
- 30 September 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 167, 115610
Tumor associated macrophages in esophageal squamous carcinoma: Promising therapeutic implications
- 30 September 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 167, 115610
Open AccessTumor associated macrophages in esophageal squamous carcinoma: Promising therapeutic implications
- Open Access
- 9 July 2023
- Published by Wiley in Thoracic Cancer
- Vol. 14 (24) , 2338-2349
18F‐FDG PET/CT predicts the role of neoadjuvant immunochemotherapy in the pathological response of esophageal squamous cell carcinoma
Background: This study aimed to investigate the predictive value of 18F‐FDG PET/CT for pathological response after neoadjuvant immunochemotherapy (NICT) in patients with esophageal squamous cell carcinoma (ESCC).Methods: The clinical data of 54 patients with ESCC who underwent two cycles of NICT followed by surgery were retrospectively analyzed. NICT consisted of PD‐1 blockade therapy combined with chemotherapy. 18F‐FDG PET/CT scans were performed before and after NICT. The pathological results after surgery were used to assess the degree of pathological response. The scan parameters of 18F‐FDG PET/CT and their changes before and after NICT were compared with the pathological response.Results: Among the 54 patients, 10 (18.5%) achieved complete pathological response (pCR) and 21 (38.9%) achieved major pathological response (MPR). The post‐NICT scan parameters and their changes were significantly associated with the pathological response. In addition, the values of the changes in the scanned parameters before and after treatment can further predict the pathological response of the patient.Conclusion: 18F‐FDG PET/CT is a useful tool to evaluate the efficacy of NICT and predict pathological response in patients with ESCC. The post‐NICT scan parameters and their changes can help identify patients who are likely to achieve pCR or MPR.
- 9 July 2023
- Published by Wiley in Thoracic Cancer
- Vol. 14 (24) , 2338-2349
Open Access18F‐FDG PET/CT predicts the role of neoadjuvant immunochemotherapy in the pathological response of esophageal squamous cell carcinoma
Background: This study aimed to investigate the predictive value of 18F‐FDG PET/CT for pathological response after neoadjuvant immunochemotherapy (NICT) in patients with esophageal squamous cell carcinoma (ESCC).Methods: The clinical data of 54 patients with ESCC who underwent two cycles of NICT followed by surgery were retrospectively analyzed. NICT consisted of PD‐1 blockade therapy combined with chemotherapy. 18F‐FDG PET/CT scans were performed before and after NICT. The pathological results after surgery were used to assess the degree of pathological response. The scan parameters of 18F‐FDG PET/CT and their changes before and after NICT were compared with the pathological response.Results: Among the 54 patients, 10 (18.5%) achieved complete pathological response (pCR) and 21 (38.9%) achieved major pathological response (MPR). The post‐NICT scan parameters and their changes were significantly associated with the pathological response. In addition, the values of the changes in the scanned parameters before and after treatment can further predict the pathological response of the patient.Conclusion: 18F‐FDG PET/CT is a useful tool to evaluate the efficacy of NICT and predict pathological response in patients with ESCC. The post‐NICT scan parameters and their changes can help identify patients who are likely to achieve pCR or MPR.
- 26 June 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (11) , 6730-6736
Three-Field Versus Two-Field Lymphadenectomy in Minimally Invasive Esophagectomy: 3-Year Survival Outcomes of a Randomized Trial
Minimally invasive esophagectomy (MIE) has been used widely for the treatment of esophageal cancer. However, the optimal extent of lymphadenectomy for esop
- 26 June 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (11) , 6730-6736
Three-Field Versus Two-Field Lymphadenectomy in Minimally Invasive Esophagectomy: 3-Year Survival Outcomes of a Randomized Trial
Minimally invasive esophagectomy (MIE) has been used widely for the treatment of esophageal cancer. However, the optimal extent of lymphadenectomy for esop
- 26 June 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (11) , 6737-6738
ASO Author Reflections: 3-Year Survival Outcomes of Lymphadenectomy in Minimally Invasive Esophagectomy
- 26 June 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (11) , 6737-6738
ASO Author Reflections: 3-Year Survival Outcomes of Lymphadenectomy in Minimally Invasive Esophagectomy